BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Tokyo:4528) Lirilumab Antibody Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) / KIR2DL2...
...that are often also expressed on T cells. It licensed its first-in-class mAb against KIR2DL1, KIR2DL2...
...Interleukin-2 KIR2DL1 - Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 KIR2DL2 - Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2...
BioCentury | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

...Business: Cancer Molecular target: Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1); KIR2DL2...
...data Milestone: NA Allison Johnson lirilumab Innate Pharma S.A. Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2 (KIR2DL2)...
BioCentury | Nov 30, 2017
Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor...
BioCentury | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

...Cancer Molecular target: Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) ; KIR2DL2...
...Co. Innate Pharma S.A. Ono Pharmaceutical Co. Ltd. Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2 (KIR2DL2)...
BioCentury | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

...Leon BMS-986015 IPH 2102 IPH2102 lirilumab Bristol-Myers Squibb Co. Innate Pharma S.A. Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2 (KIR2DL2) EffiKIR...
BioCentury | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

...Cancer Molecular target: Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) ; KIR2dL2...
...PFS) and pharmacokinetics Status: Phase I/II trial Milestone: NA Meghan Sullivan BMS-986015 IPH2102 lirilumab Bristol-Myers Innate Pharma Ono Pharmaceutical Killer cell immunoglobulin-like receptors (KIRs) KIR2DL1 KIR2DL2 Society...
BioCentury | Nov 4, 2016
Clinical News

IPH4102: Preliminary Ph I data

Preliminary data from 16 evaluable patients with KIR3dL2-positive, relapsed or refractory CTCL in the dose-escalation portion of the open-label, international Phase I IPH4102-101 trial showed that 0.0001-1.5 mg/kg doses of IV IPH4102 were well tolerated...
BioCentury | Oct 10, 2016
Clinical News

Lirilumab: Phase II ongoing

...Cancer Molecular target: Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1) ; Killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 2...
Items per page:
1 - 10 of 26